Sanofi, which recently announced plans to invest at least $20 billion in the U.S. through 2030, has acquired Vigil Neuroscience Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, for approximately $470 million. This acquisition in neurology, one of Sanofi’s four strategic disease areas, enhances Sanofi’s early-stage pipeline and includes VG-3927, which will be evaluated in a phase 2 clinical study in Alzheimer’s d...